The DHU Hepatinov is the coordinating structure of the iLiTE project for University Hospital Research in Health (RHU). It has just been awarded €8.5 million in funding for its innovation project for Liver Tissue Engineering.
The French Institute of BioFabrication, created at the initiative of Hépatinov, aims to build organs by bioengineering, and therefore represents Hépatinov in the execution of the iLite project. As such, The IFBF Institute is recruiting doctoral and post-doctoral researchers for the various work packages included in this project, namely:
* Imaging, image analysis, in silico models, and software generation (WP1)
* Liver tissue/organoids (WP2)
* Construction of biliary duct network (WP3)
* In vitro construction of a vascular network (WP4)
* Integration of liver organoids into vascular and/or biliary networks and scale-up (WP5)
* Liver-on-chip (WP6)
* External bio-artificial liver (WP7)
* Safety/GMP/Industrialization (WP8)
The workplace will be mainly in the Paris region but some positions are also available in the provinces. The first recruitments are scheduled for early October 2016. To apply, write by email to:
* Professor Jean-Charles Duclos-Vallée, Hépatinov Coordinator, « jean-charles.duclos-vallee@ifbf-Institute.org »
* Professor Dominique Franco, IFBF Institute President, « dominique.franco@ifbf-Institute.org »
The DHU Hepatinov is the coordinating structure of the iLiTE project for University Hospital Research in Health (RHU). It has just been awarded €8.5 million in funding for its innovation project for Liver Tissue Engineering.
The international jury of the RHU (University Hospital Health Research) second call for projects of the Future Investments Program decided to fund 10 projects of which iLiTE (innovations in Liver Tissue Engineering).
The RHU program supports translational projects involving academic research, hospitals and businesses. The 10 funded projects will help strengthen the links between basic research with clinical but also industrial applications, and are part of the national strategy for research and health designed by the Government.
iLiTE (innovations in Liver Tissue Engineering), the driver of which is the Hepatinov DHU, brings together teams of the Paul-Brousse and Saint-Louis hospitals, University of Paris Saclay, CEA, INSERM, INRIA and four companies. All these actors are members of CellSpace who pooled their energies and ambitions. This achievement confirms the validity of the CellSpace strategy to bring together the expertise in medecine, biology, physical sciences and engineering in order to encourage the creation of bioengineered organs.
See the press release (French)
The international jury of the RHU (University Hospital Health Research) second call for projects of the Future Investments Program decided to fund 10 projects of which iLiTE (innovations in Liver Tissue Engineering).
As part of the “semaine de l’industrie” event (http://www.entreprises.gouv.fr/semaine-industrie), held from the 16th to the 20th of March 2016, Dominique Franco, President of the French Institute of BioFabrication, gives a presentation on producing bioengineered organs, on Saturday, 19th of March, 2016, from 3.00 pm to 5.00 pm, in the premises of the Sup’Biotech school, 66 rue Guy Moquet in Villejuif.
As part of the “semaine de l’industrie” event (http://www.entreprises.gouv.fr/semaine-industrie), held from the 16th to the 20th of March 2016, Dominique Franco, President of the French Institute of BioFabrication, gives a presentation on producing bioengineered organs, on Saturday, 19th of March, 2016, from 3.00 pm to 5.00 pm, in the premises of the Sup’Biotech school, 66 rue Guy Moquet in Villejuif.
Download the overview (text in French):